OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Oxford Biomedica PLC/  GB00BDFBVT43  /

Nasdaq Other OTC
6/4/2024  3:52:49 PM Chg. - Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
4.3100USD - 2,000
Turnover: 8,620		 -Bid Size: - -Ask Size: - 356.52 mill.USD - -
GlobeNewswire 4/1 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 3/18 Homology Medicines Declares Distribution to Common Stockholders
GlobeNewswire 3/6 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire 3/5 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire 1/29 Oxford Biomedica completes acquisition of ABL Europe
GlobeNewswire 1/23 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire 1/7 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire 1/3 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire 12/7/2023 Business Update
GlobeNewswire 12/4/2023 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire 11/16/2023 Q32 Bio and Homology Medicines Announce Merger Agreement
GlobeNewswire 11/14/2023 Homology Medicines Reports Third Quarter 2023 Financial Results
GlobeNewswire 11/9/2023 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 9/20/2023 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire 9/20/2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire 9/7/2023 Oxford Biomedica to host webinar showcasing the TetraVecta™ system
GlobeNewswire 3/23/2022 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire 3/17/2022 Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...
GlobeNewswire 3/11/2022 Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solution...
GlobeNewswire 3/10/2022 Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Cap...
GlobeNewswire 1/31/2022 Oxford Biomedica announces update to agreement with Sio Gene Therapies
GlobeNewswire 1/31/2022 Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosido...
GlobeNewswire 1/28/2022 Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ establ...
GlobeNewswire 1/28/2022 Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ establ...
GlobeNewswire 1/17/2022 John Dawson to retire from Oxford Biomedica